8-K Announcements
6Material company update
May 19, 2026·SEC
Material company update
May 8, 2026·SEC
Material company update
May 8, 2026·SEC
Artiva Biotherapeutics, Inc.(ARTV)Earnings, Financials & Key Ratios
ARTV•NASDAQ
Price updated Jun 19, 2026
AboutArtiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Show more
- Revenue$0-100.0%
- EBITDA-$88M-35.7%
- Net Income-$84M-43.4%
- EPS (Diluted)-3.43+34.0%
- ROE-56.55%+88.1%
ARTV Key Insights
Artiva Biotherapeutics, Inc. (ARTV) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 96 (top 4%)
✗Weaknesses
- ✗Profits declining 36.1% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ARTV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ARTV Price & Volume
Artiva Biotherapeutics, Inc. (ARTV) stock price & volume — 10-year historical chart
Loading chart...
ARTV Growth Metrics
Artiva Biotherapeutics, Inc. (ARTV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-34.28%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-11.29%
Return on Capital
10 Years-53.32%
5 Years-48.41%
3 Years-44.83%
Last Year-57.5%
ARTV Recent Earnings
Artiva Biotherapeutics, Inc. (ARTV) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (38%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$0.95-8.0%
$0.88
Rev
—
—
Q2 2026
Mar 10, 2026Metric
Actual
Est
EPS
$0.84+3.4%
$0.87
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.88+4.3%
$0.92
Rev
—
—
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.87-3.6%
$0.84
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.95vs $0.88-8.0% | — |
| Q2 2026 | Mar 10, 2026 | $0.84vs $0.87+3.4% | — |
| Q4 2025 | Nov 12, 2025 | $0.88vs $0.92+4.3% | — |
| Q3 2025 | Aug 6, 2025 | $0.87vs $0.84-3.6% | — |
Based on last 12 quarters of dataView full earnings history →
ARTV Peer Comparison
Artiva Biotherapeutics, Inc. (ARTV) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 STTK | 237.12M | 4.95 | -7.07 | -82.52% | -49.87% | -60.73% | 0.02 | |
 IOVA | 1.4B | 3.91 | -3.59 | 60.6% | -123.9% | -50.17% | 0.07 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 |
Compare ARTV vs Peers
Artiva Biotherapeutics, Inc. (ARTV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ARTV Income Statement
Artiva Biotherapeutics, Inc. (ARTV) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 2M | 4.93M | 33.49M | 251K | 0 | 0 |
Revenue Growth % | - | - | 146.3% | 579.21% | -99.25% | -100% | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 2.6M | 666K |
COGS % of Revenue | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 2M▲ 0% | 4.93M▲ 146.3% | 33.49M▲ 579.2% | 251K▼ 99.3% | -2.6M▼ 1134.7% | -666K▲ 0% |
Gross Margin % | - | 100% | 100% | 100% | 100% | - | - |
Gross Profit Growth % | - | - | 146.3% | 579.21% | -99.25% | -1134.66% | - |
Operating Expenses | 18.27M | 55.27M | 64.76M | 64.16M | 67.53M | 88.01M | 91.4M |
OpEx % of Revenue | - | 2760.94% | 1313.32% | 191.58% | 26905.58% | - | - |
Selling, General & Admin | 4.43M | 12.86M | 20.78M | 13.91M | 17.2M | 20.27M | 20.27M |
SG&A % of Revenue | - | 642.56% | 421.33% | 41.54% | 6854.58% | - | - |
Research & Development | 13.85M | 42.41M | 43.98M | 50.25M | 50.33M | 69.54M | 71.8M |
R&D % of Revenue | - | 2118.38% | 891.99% | 150.04% | 20051% | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -1.8M | -666K |
Operating Income | -18.27M▲ 0% | -53.27M▼ 191.6% | -59.83M▼ 12.3% | -30.67M▲ 48.7% | -67.28M▼ 119.4% | -90.61M▼ 34.7% | -92.07M▲ 0% |
Operating Margin % | - | -2660.94% | -1213.32% | -91.58% | -26805.58% | - | - |
Operating Income Growth % | - | -191.57% | -12.31% | 48.74% | -119.37% | -34.67% | - |
EBITDA | -18.2M | -53.02M | -58.67M | -28.41M | -64.85M | -88.01M | -89.43M |
EBITDA Margin % | - | -2648.55% | -1189.84% | -84.81% | -25837.05% | - | - |
EBITDA Growth % | - | -191.37% | -10.65% | 51.59% | -128.31% | -35.72% | -23.37% |
D&A (Non-Cash Add-back) | 73K | 248K | 1.16M | 2.27M | 2.43M | 2.6M | 2.63M |
EBIT | -17.59M | -71.83M | -59.83M | -30.67M | -67.28M | -90.61M | -92.07M |
Net Interest Income | -197K | 0 | 1.29M | 2.54M | 5.35M | 5.96M | 5.01M |
Interest Income | 2K | 0 | 1.29M | 2.54M | 5.35M | 5.96M | 5.01M |
Interest Expense | 199K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 280K | -18.55M | 1.49M | 3.05M | 8.79M | 6.75M | 5M |
Pretax Income | -17.99M▲ 0% | -71.83M▼ 299.2% | -58.34M▲ 18.8% | -27.62M▲ 52.6% | -58.49M▼ 111.7% | -83.86M▼ 43.4% | -87.07M▲ 0% |
Pretax Margin % | - | -3587.66% | -1183.03% | -82.48% | -23303.98% | - | - |
Income Tax | 0 | 0 | 53K | 72K | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | -0.09% | -0.26% | 0% | 0% | 0% |
Net Income | -17.99M▲ 0% | -71.83M▼ 299.2% | -58.39M▲ 18.7% | -27.7M▲ 52.6% | -58.49M▼ 111.2% | -83.86M▼ 43.4% | -87.07M▲ 0% |
Net Margin % | - | -3587.66% | -1184.1% | -82.69% | -23303.98% | - | - |
Net Income Growth % | - | -299.23% | 18.71% | 52.57% | -111.2% | -43.38% | -34.28% |
Net Income (Continuing) | -17.99M | -71.83M | -58.39M | -27.7M | -58.49M | -83.86M | -87.07M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.02▲ 0% | -4.08▼ 300.0% | -3.32▲ 18.6% | -1.19▲ 64.2% | -5.20▼ 337.0% | -3.43▲ 34.0% | -3.53▲ 0% |
EPS Growth % | - | -300% | 18.63% | 64.16% | -336.97% | 34.04% | -11.29% |
EPS (Basic) | -1.02 | -4.08 | -3.32 | -1.19 | -5.20 | -3.43 | - |
Diluted Shares Outstanding | 17.58M | 17.58M | 17.58M | 23.28M | 24.36M | 24.44M | 24.68M |
Basic Shares Outstanding | 17.58M | 17.58M | 17.58M | 23.28M | 24.36M | 24.44M | 24.68M |
Dividend Payout Ratio | - | - | - | - | - | - | - |
ARTV Balance Sheet
Artiva Biotherapeutics, Inc. (ARTV) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Total Current Assets | 26.11M | 162.29M | 104.67M | 79.82M | 188.63M | 112.67M | 88.74M |
Cash & Short-Term Investments | 25.44M | 160.92M | 102.53M | 76.97M | 185.43M | 108.01M | 86.78M |
Cash Only | 25.44M | 160.92M | 102.53M | 53.5M | 40.23M | 26.7M | 20.95M |
Short-Term Investments | 0 | 0 | 0 | 23.47M | 145.19M | 81.31M | 65.83M |
Accounts Receivable | 0 | 468K | 525K | 1.76M | 146K | 0 | 0 |
Days Sales Outstanding | - | 85.32 | 38.86 | 19.16 | 212.31 | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 1.62M | 1.09M | 3.06M | 4.66M | 1.96M |
Total Non-Current Assets | 3.13M | 7.64M | 28.37M | 25.29M | 20.95M | 18.27M | 17.21M |
Property, Plant & Equipment | 2.39M | 4.08M | 27.61M | 24.64M | 20.43M | 17.36M | 16.3M |
Fixed Asset Turnover | - | 0.49x | 0.18x | 1.36x | 0.01x | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 461K |
Other Non-Current Assets | 732K | 3.56M | 762K | 650K | 525K | 919K | 919K |
Total Assets | 29.23M▲ 0% | 169.93M▲ 481.3% | 133.05M▼ 21.7% | 105.11M▼ 21.0% | 209.58M▲ 99.4% | 130.94M▼ 37.5% | 105.95M▲ 0% |
Asset Turnover | - | 0.01x | 0.04x | 0.32x | 0.00x | - | 0.00x |
Asset Growth % | - | 481.26% | -21.7% | -21% | 99.38% | -37.52% | 7% |
Total Current Liabilities | 5.76M | 19.3M | 25.63M | 12.23M | 12.25M | 13.09M | 10.88M |
Accounts Payable | 2.15M | 1.44M | 1.1M | 614K | 1.12M | 0 | 2.29M |
Days Payables Outstanding | - | - | - | - | - | - | 595.87 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 3.06M | 3.04M |
Deferred Revenue (Current) | 0 | 7.29M | 10.89M | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 10.03M | 5.56M |
Current Ratio | 4.53x | 8.41x | 4.08x | 6.53x | 15.39x | 8.61x | 8.16x |
Quick Ratio | 4.53x | 8.41x | 4.08x | 6.53x | 15.39x | 8.61x | 8.16x |
Cash Conversion Cycle | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 45.04M | 239.48M | 248.13M | 254.9M | 10.69M | 7.88M | 7.23M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 7.88M | 7.23M |
Capital Lease Obligations | 1.66M | 1.31M | 15.96M | 13.32M | 10.61M | 0 | 18.1M |
Deferred Tax Liabilities | 0 | 216.41M | 216.41M | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 43.38M | 81K | 115K | 241.59M | 73K | 0 | 0 |
Total Liabilities | 50.8M | 258.78M | 273.75M | 267.13M | 22.94M | 20.97M | 18.11M |
Total Debt | 2.12M | 1.74M | 19.45M | 16.91M | 14.35M | 10.94M | 10.26M |
Net Debt | -23.33M | -159.18M | -83.08M | -36.59M | -25.88M | -15.76M | -10.69M |
Debt / Equity | - | - | - | - | 0.08x | 0.10x | 0.12x |
Debt / EBITDA | - | - | - | - | - | - | -0.11x |
Net Debt / EBITDA | - | - | - | - | - | - | 0.12x |
Interest Coverage | -88.42x | - | - | - | - | - | - |
Total Equity | -21.57M▲ 0% | -88.86M▼ 312.0% | -140.7M▼ 58.3% | -162.01M▼ 15.2% | 186.64M▲ 215.2% | 109.97M▼ 41.1% | 87.85M▲ 0% |
Equity Growth % | - | -312.01% | -58.34% | -15.15% | 215.2% | -41.08% | 53.25% |
Book Value per Share | -1.23 | -5.05 | -8.00 | -6.96 | 7.66 | 4.50 | 3.56 |
Total Shareholders' Equity | -21.57M | -88.86M | -140.7M | -162.01M | 186.64M | 109.97M | 87.85M |
Common Stock | 0 | 0 | 0 | 0 | 3K | 3K | 3K |
Retained Earnings | -21.98M | -93.8M | -152.59M | -181.31M | -246.68M | -330.55M | -354.06M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 308K | -129K | 103K | -18K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ARTV Cash Flow Statement
Artiva Biotherapeutics, Inc. (ARTV) cash flow — operating, investing & free cash flow history
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Cash from Operations | -13.54M | -15.3M | -50.83M | -47.43M | -55.03M | -76.75M | -77.86M |
Operating CF Margin % | - | -764.44% | -1030.81% | -141.62% | -21925.1% | - | - |
Operating CF Growth % | - | -13.02% | -232.13% | 6.69% | -16.03% | -39.47% | -139.42% |
Net Income | -17.99M | -71.83M | -58.79M | -28.72M | -65.37M | -83.86M | -87.07M |
Depreciation & Amortization | 73K | 248K | 1.16M | 2.27M | 2.43M | 717K | 2.71M |
Stock-Based Compensation | 297K | 4.31M | 6.58M | 7.05M | 6.98M | 6.82M | 4.77M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -278K | 18.55M | 4.08M | 251K | 1.25M | 0 | 6.12M |
Working Capital Changes | 4.36M | 33.41M | -3.87M | -28.28M | -325K | -424K | -4.39M |
Change in Receivables | 0 | -468K | -57K | -1.23M | 1.61M | 79K | 183K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 1.82M | -1.24M | 190K | -408K | 519K | -760K | 1.01M |
Cash from Investing | -284K | -1.72M | -6.3M | -25.98M | -120.46M | 63.41M | 68.76M |
Capital Expenditures | -284K | -1.72M | -6.3M | -3.26M | -642K | -2.59M | -2.32M |
CapEx % of Revenue | - | 86.11% | 127.74% | 9.73% | 255.78% | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 37.4M | 152.75M | -1.26M | 24.39M | 162.23M | 9K | -342K |
Debt Issued (Net) | 3M | 0 | 0 | 0 | -149K | -132K | -66K |
Equity Issued (Net) | 34.85M | 154.61M | -5K | -12K | 162.32M | 371K | 131K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | -5K | -12K | -4.18M | 0 | 0 |
Other Financing | -459K | -1.86M | -1.26M | 24.4M | 51K | -230K | -407K |
Net Change in Cash | 23.57M▲ 0% | 135.73M▲ 475.8% | -58.39M▼ 143.0% | -49.01M▲ 16.1% | -13.27M▲ 72.9% | -13.33M▼ 0.5% | -9.45M▲ 0% |
Free Cash Flow | -13.82M▲ 0% | -17.03M▼ 23.2% | -57.13M▼ 235.5% | -50.69M▲ 11.3% | -55.67M▼ 9.8% | -79.34M▼ 42.5% | -80.18M▲ 0% |
FCF Margin % | - | -850.55% | -1158.55% | -151.34% | -22180.88% | - | - |
FCF Growth % | - | -23.17% | -235.49% | 11.27% | -9.84% | -42.5% | -31.61% |
FCF per Share | -0.79 | -0.97 | -3.25 | -2.18 | -2.29 | -3.25 | -3.25 |
FCF Conversion (FCF/Net Income) | 0.75x | 0.21x | 0.87x | 1.71x | 0.94x | 0.92x | 0.92x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 83K | 0 | 0 | 0 |
ARTV Key Ratios
Artiva Biotherapeutics, Inc. (ARTV) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | - | -475.05% | -56.55% | -73.16% |
Return on Invested Capital (ROIC) | - | - | - | - | -53.31% | -65.67% |
Gross Margin | 100% | 100% | 100% | 100% | - | - |
Net Margin | -3587.66% | -1184.1% | -82.69% | -23303.98% | - | - |
Debt / Equity | - | - | - | 0.08x | 0.10x | 0.12x |
FCF Conversion | 0.21x | 0.87x | 1.71x | 0.94x | 0.92x | 0.92x |
Revenue Growth | - | 146.3% | 579.21% | -99.25% | -100% | - |
Related:ARTV Dividend History·ARTV Revenue History·ARTV Price History·ARTV P/E History·ARTV Financial Ratios·ARTV Institutional Holders
ARTV SEC Filings & Documents
Artiva Biotherapeutics, Inc. (ARTV) SEC filings — annual & quarterly reports (10-K, 10-Q)
ARTV Frequently Asked Questions
Artiva Biotherapeutics, Inc. (ARTV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Artiva Biotherapeutics, Inc. (ARTV) saw revenue decline by 100.0% over the past year.
Artiva Biotherapeutics, Inc. (ARTV) reported a net loss of $87.1M for fiscal year 2025.
Dividend & Returns
Artiva Biotherapeutics, Inc. (ARTV) has a return on equity (ROE) of -56.5%. Negative ROE indicates the company is unprofitable.
Artiva Biotherapeutics, Inc. (ARTV) had negative free cash flow of $80.2M in fiscal year 2025, likely due to heavy capital investments.